GURUFOCUS.COM » STOCK LIST » Technology » Software » Enfusion Inc (NYSE:ENFN) » Definitions » FCF Margin %

Enfusion (Enfusion) FCF Margin % : 9.23% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Enfusion FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Enfusion's Free Cash Flow for the three months ended in Dec. 2023 was $4.3 Mil. Enfusion's Revenue for the three months ended in Dec. 2023 was $46.5 Mil. Therefore, Enfusion's FCF Margin % for the quarter that ended in Dec. 2023 was 9.23%.

As of today, Enfusion's current FCF Yield % is 1.85%.

The historical rank and industry rank for Enfusion's FCF Margin % or its related term are showing as below:

ENFN' s FCF Margin % Range Over the Past 10 Years
Min: -7.46   Med: 4.14   Max: 13.34
Current: 9.15


During the past 5 years, the highest FCF Margin % of Enfusion was 13.34%. The lowest was -7.46%. And the median was 4.14%.

ENFN's FCF Margin % is ranked better than
71.77% of 2774 companies
in the Software industry
Industry Median: 1.205 vs ENFN: 9.15


Enfusion FCF Margin % Historical Data

The historical data trend for Enfusion's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enfusion FCF Margin % Chart

Enfusion Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
13.34 -4.28 -7.46 4.14 9.15

Enfusion Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.25 -3.97 8.89 21.41 9.23

Competitive Comparison of Enfusion's FCF Margin %

For the Software - Application subindustry, Enfusion's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enfusion's FCF Margin % Distribution in the Software Industry

For the Software industry and Technology sector, Enfusion's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Enfusion's FCF Margin % falls into.



Enfusion FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Enfusion's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=15.963/174.535
=9.15 %

Enfusion's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=4.291/46.486
=9.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enfusion FCF Margin % Related Terms

Thank you for viewing the detailed overview of Enfusion's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Enfusion (Enfusion) Business Description

Traded in Other Exchanges
N/A
Address
125 South Clark Street, Suite 750, Chicago, IL, USA, 60603
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute better-informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth.
Executives
Deirdre Somers director C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Bradley Herring officer: Chief Financial Officer C/O SHIFT4 PAYMENTS, INC., 2202 N. IRVING STREET, ALLENTOWN PA 16109
Oleg Movchan director, 10 percent owner C/O ENFUSION INC., 125 SOUTH CLARK ST. STE 750, CHICAGO IL 60603
Bronwen Bastone officer: Chief People Officer C/O ENFUSION, INC., 125 SOUTH CLARK STREET SUITE 750, CHICAGO IL 60603
Stephen Malherbe 10 percent owner C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Dan Groman officer: Chief Technology Officer C/O ENFUSION INC., 125 SOUTH CLARK STREET STE. 750, CHICAGO IL 60603
Tarek Hammoud 10 percent owner C/O ENFUSION INC., 125 SOUTH CLARK ST. STE. 750, CHICAGO IL 60603
Ftv Investment Holdings, L.p. 10 percent owner 601 CALIFORNIA STREET, FLOOR 19, SAN FRANCISCO CA 94108
Michael Spellacy director 399 PARK AVENUE, NEW YORK NY 10022
Quiet Light Securities, Llc 10 percent owner 70 WEST MADISON, SUITE 1675, CHICAGO IL 60602
Steven M. Bachert officer: Chief Revenue Officer C/O ENFUSION INC., 125 SOUTH CLARK ST., STE 750, CHIGAGO IL 60603
Lra Ventures, Llc 10 percent owner C/O ENFUSION, INC., 125 SOUTH CLARK STREET, SUITE 750, CHICAGO IL 60603
Hillhouse Investment Management, Ltd. 10 percent owner OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
Roy Luo director 394 PACIFIC AVENUE, 2ND FLOOR, SAN FRANCISCO CA 94111
Iconiq Strategic Partners V-b, L.p. 10 percent owner 394 PACIFIC AVENUE, SECOND FLOOR, SAN FRANCISCO CA 94111

Enfusion (Enfusion) Headlines

From GuruFocus

Enfusion Announces Date of Fourth Quarter and Full Year 2022 Results

By Business Wire Business Wire 02-09-2023

Enfusion Appoints Oleg Movchan Interim Chief Executive Officer

By Business Wire Business Wire 08-22-2022

Enfusion to Present at Upcoming Investor Events

By Business Wire Business Wire 05-02-2022

Enfusion Welcomes New Addition to Board of Directors

By Business Wire Business Wire 11-30-2022

Enfusion Names Oleg Movchan as Chief Executive Officer

By Business Wire Business Wire 12-22-2022